Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Operating Leases (2019 - 2025)

Historic Operating Leases for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Q3 2025 value amounting to $2.5 million.

  • Catalyst Pharmaceuticals' Operating Leases fell 1481.48% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year decrease of 1481.48%. This contributed to the annual value of $2.8 million for FY2024, which is 1260.98% down from last year.
  • As of Q3 2025, Catalyst Pharmaceuticals' Operating Leases stood at $2.5 million, which was down 1481.48% from $2.6 million recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' Operating Leases peaked at $4.3 million during Q1 2021, and registered a low of $2.5 million during Q3 2025.
  • Its 5-year average for Operating Leases is $3.5 million, with a median of $3.7 million in 2023.
  • In the last 5 years, Catalyst Pharmaceuticals' Operating Leases surged by 361062.21% in 2021 and then plummeted by 2269.32% in 2025.
  • Catalyst Pharmaceuticals' Operating Leases (Quarter) stood at $4.2 million in 2021, then dropped by 7.33% to $3.9 million in 2022, then fell by 18.13% to $3.2 million in 2023, then dropped by 12.61% to $2.8 million in 2024, then dropped by 11.67% to $2.5 million in 2025.
  • Its Operating Leases was $2.5 million in Q3 2025, compared to $2.6 million in Q2 2025 and $2.7 million in Q1 2025.